TCRX
TScan Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.22 EPS, $1.70M rev
Last earnings +3.3% on 2026-05-06
$0.97
▲ +15.33%$0.97▼ -32.72%
over 1Y
L $0.84EODHDH $2.48
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+15.3%
1W+15.3%
1M-9.5%
3M-2.0%
YTD-5.0%
1Y-32.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Revenue grew 266.7% YoY; but unprofitable (net margin -1256.8%).
TScan Therapeutics, Inc. shows $10.3M in FY2025 revenue (+266.7% YoY), a -1256.8% net margin, and -105.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $10.1M | $13.5M | $21.0M | $2.82M | $10.3M |
| Gross profit | — | — | — | — | — |
| Operating income | -$48.6M | -$66.6M | -$93.5M | -$135M | -$136M |
| Net income | -$48.6M | -$66.2M | -$89.2M | -$127M | -$130M |
| Diluted EPS | -$4.17 | -$2.75 | -$1.36 | -$1.14 | -$1.00 |
| Net margin | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$93.3M
EV / EBITDA—
EV / Sales-9.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-558.6%
FCF yield-601.5%
Quality & risk
ROIC (est.)-67.5%
Free cash flow-$140M
Total debt$35.9M
Net cash$117M
Altman Z-Score-4.14 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-222026-06-22open ↗4Period ending 2026-05-202026-05-22open ↗8-KPeriod ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-06open ↗8-KPeriod ending 2026-05-062026-05-06open ↗ARSPeriod ending 2025-12-312026-04-17open ↗
Frequently asked
- Is TScan Therapeutics, Inc. (TCRX) a buy?
- TCRX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 266.7% YoY; but unprofitable (net margin -1256.8%).
- What is TScan Therapeutics, Inc.'s quality score?
- TCRX scores 52.647058823529406/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001783328, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 4:55:22 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.